Interview with Wolf Kupatt, Managing Director, Baxter Germany
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
Address: Sanofi-Aventis Deutschland GmbH
Industriepark Höchst, K703
65926 Frankfurt
,Germany
Tel: 0180 / 2 222010
Web: http://www.sanofi.de/l/de/de/index.jsp
The Sanofi-Aventis Deutschland GmbH is the German subsidiary of one of the world’s leading pharmaceutical companies. The Group employs approximately 100,000 employees worldwide and maintains strong market positions in the regions of North America, Europe and Asia. Its core business is the original innovative prescription drugs for the treatment (drugs) and prevention (vaccines) of serious, widespread diseases. The R & D expenditures by sanofi-aventis in 2008 amounted to 4.6 billion euros, of which, the Sanofi-Aventis Deutschland GmbH about 600 million euros worn. But not only the high use of resources is decisive – the research from sanofi-aventis is one of the most productive and successful worldwide. Currently, sanofi-aventis 65 novel drugs and vaccines in development. Of these 27 projects are in advanced clinical stage III or in the admission process. The focus is on seven core therapeutic areas: diabetes / metabolism, cardiovascular, thrombosis, central nervous system, internal medicine, oncology and vaccines. In Germany, one of sanofi-aventis with sales (including export) of 4.0 billion euros of the leading providers of innovative medicines.
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea…
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities…
Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in…
As part of the PKV – the German Association of Private Health Insurance – could you briefly introduce to our readers the German private health care system and its main…
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
You have been leading GSK, one of the top five pharmaceutical companies in the German market, for just over a year, after having worked previously in Poland, the UK, France,…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
See our Cookie Privacy Policy Here
